Program
STSP-0601
A development code. Also written as “STSP-0601 for Injection”.
Its studies are mostly in Hemophilia A, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals | 40 open or running | phase 2since Aug 25, 2021 | Feb 5, 2021 | none ahead |
| Jiangsu BioJeTay Biotechnology | 11 open or running | phase 3since Mar 13, 2025 | Mar 13, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2021First study: phase 1 study in Hemophilia ANew to Staidson (Beijing) BiopharmaceuticalsStaidson (Beijing) Biopharmaceuticals · NCT04747964 · 16 enrolled · China
- Aug 25, 2021Phase 2 study in Hemophilia AStaidson (Beijing) Biopharmaceuticals · NCT05027230 · 77 enrolled · China
- Nov 9, 2022Phase 2 study in Hemophilia AStaidson (Beijing) Biopharmaceuticals · NCT05619926 · 32 enrolled · China
- Feb 23, 2024Phase 2 study in Hemophilia AStaidson (Beijing) Biopharmaceuticals · NCT06289166 · 25 enrolled · China
- Mar 13, 2025Jiangsu BioJeTay Biotechnology's first study: phase 3 study in Hemophilia ANew to Jiangsu BioJeTay BiotechnologyJiangsu BioJeTay Biotechnology · NCT06922045 · 40 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06922045Hemophilia A · China | 3 | Active, not recruiting | Jiangsu BioJeTay Biotechnology | Sep 2026 | 40 |
| NCT06289166Hemophilia A · China | 2 | Completed | Staidson (Beijing) Biopharmaceuticals | Oct 17, 2024 | 25 |
| NCT05619926Hemophilia A · China | 2 | Completed | Staidson (Beijing) Biopharmaceuticals | Aug 25, 2023 | 32 |
| NCT05027230Hemophilia A · China | 2 | Completed | Staidson (Beijing) Biopharmaceuticals | Jul 15, 2023 | 77 |
| NCT04747964Hemophilia A · China | 1 | Completed | Staidson (Beijing) Biopharmaceuticals | Apr 19, 2021 | 16 |
How it is read
Names in the registry
- “STSP-0601 for Injection”, 11 entries
Codes read as this program: STSP0601.
Conditions, from the studies’ own filings
- Hemophilia A, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.